
    
      This is a phase 2a randomized double-blinded placebo-controlled cross-over design study in
      patients with idiopathic pruritus ani. 24 patients, male and females, aged 18 -65 with severe
      idiopathic pruritus ani (VAS score above 60), will be randomized to this study.

      Patients that meet all inclusion criteria and do not have exclusion criteria at randomization
      visit will be randomly assigned to one of the two treatment groups:

      Group 1 will receive 3 weeks of RDD1609 for 3 weeks, followed by 3 weeks of treatment with
      placebo.

      Group 2 will receive 3 weeks of treatment with placebo followed by 3 weeks of treatment with
      RDD1609.
    
  